ReviewAnnals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology2020
Asthma biologics: Comparing trial designs, patient cohorts and study results.
Review in Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Biologic effectiveness increases with earlier biologic initiation after severe asthma onset.The journal of allergy and clinical immunology. Global · 2026Article
- Immune dysregulation in endometriosis: the T cell perspective.Frontiers in immunology · 2026Review
- Early-life viral infections and asthma: new cells and ideas.Current opinion in pediatrics · 2025Review
- Detection and prediction of real-world severe asthma phenotypes by application of machine learning to electronic health records.The journal of allergy and clinical immunology. Global · 2025Article
- The Comparative Effectiveness of Mepolizumab and Benralizumab in the Treatment of Eosinophilic Asthma.Advances in respiratory medicine · 2025Article
- Exploring Perceptions of Biologic Therapies: A Qualitative Study Among Canadians Living with Severe Asthma.Advances in therapy · 2024Article
- Airways Type-2 Related Disorders: Multiorgan, Systemic or Syndemic Disease?International journal of molecular sciences · 2024Review
- Comprehensive evaluation of type 2 endotype and clinical features in patients with chronic rhinosinusitis with nasal polyps in Taiwan: a cross-sectional study.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2023Article
- Nationwide trends in hospitalization, medical costs, and mortality for asthma after introduction of biologics: A cross-sectional study in the United States.Journal of managed care & specialty pharmacy · 2023Article
- A Charter to Fundamentally Change the Role of Oral Corticosteroids in the Management of Asthma.Advances in therapy · 2023Review
- Switching Biological Therapies in Severe Asthma.International journal of molecular sciences · 2023Review
- The multidisciplinary approach to eosinophilia.Frontiers in oncology · 2023Review
- Clinical endpoints in allergen immunotherapy: State of the art 2022.Allergologie select · 2023Review
- Therapeutic Strategies of Biologics in Chronic Rhinosinusitis: Current Options and Future Targets.International journal of molecular sciences · 2022Review
- Diagnosis and management of asthma in children.BMJ paediatrics open · 2022Review
- Dupilumab Treatment for Asthma: On the Road to a New Horizon Beyond Ethnic Differences?Allergy, asthma & immunology research · 2022Article
- Appraisal of the Real-World Effectiveness of Biologic Therapies in Aspirin-Exacerbated Respiratory Disease.The journal of allergy and clinical immunology. In practice · 2022Article
- Patient Preferences for Attributes of Biologic Treatments in Moderate to Severe Asthma: A Discrete Choice Experiment Study.Patient preference and adherence · 2022Article
- Impact of Therapeutics on Unified Immunity During Allergic Asthma and Respiratory Infections.Frontiers in allergy · 2022Review
- Obesity, Inflammation, and Severe Asthma: an Update.Current allergy and asthma reports · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveFive biologic therapies have FDA-approved indications for difficult-to-control asthma. The clinical trials that proved the efficacy and safety of these biologics were often similar in their inclusion criteria, study designs, and endpoints. Many of these trials have been reanalyzed post hoc to identify subsets of subjects considered to be enhanced responders. As a result, keeping up with the literature and deciding on the most appropriate biologic for our patients has become increasingly difficult. This review summarizes and compares trial designs, patient cohorts, and study results of the major trials involving these therapies. DATA SOURCES: Included are basic science articles, online Food and Drug Administration (FDA) applications, and all the published reports of phase II and phase III clinical trials for FDA-approved asthma biologics. STUDY SELECTIONS: Included are the major phase II and phase III clinical trials of 5 asthma biologics.
resultsBecause of variations in inclusion criteria and natural variations in enrolled cohorts, the baseline clinical traits and severity of study populations in asthma biologic trials differed significantly, which is important because baseline annualized exacerbation rates and blood eosinophilia are both strong predictors of a biologic's success. Notwithstanding, the trial results, when considered together, can help guide care providers in choosing the most appropriate biologic for our patients.
conclusionUnderstanding the details and differences in asthma biologic trial designs, patient cohorts, and in study results will help care providers make more informed decisions when choosing a biologic. We are hopeful this review will serve as a reference to care providers for this purpose.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.